aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report second quarter 2021 financial results and provide a corporate update after the market close on Tuesday, August 10, 2021. Management will host a conference call and webcast to review the results and provide an operational update.
Conference Call and Webcast Details:
Tuesday, August 10th @ 5:00 pm EDT / 2:00 pm PDT
Conference ID: 4692110
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr's research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr's primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications firstname.lastname@example.org